Manipulation of immunity to and pathology of respiratory infections

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 3, 2004, Pages 413-426

  Snelgrove, Robert ^a   Williams, Andrew ^a   Thorpe, Callum ^a   Hussell, Tracy ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti TNF; Immune modulation; Immunopathology; Influenza virus; Lung; OX40; Respiratory syncytial virus

Indexed keywords

AMANTADINE; CD4 ANTIGEN; CD8 ANTIGEN; COLLECTIN; CYTOKINE; DEFENSIN; HISTAMINE; IMMUNOGLOBULIN A; INFLIXIMAB; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; LIPOPOLYSACCHARIDE; LYSOVIR; LYSOZYME; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NITRIC OXIDE; OSELTAMIVIR; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; RIMANTADINE; SCAVENGER RECEPTOR; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZANAMIVIR;

ANTIGEN PRESENTING CELL; CAUSE OF DEATH; CHILL; COUGHING; DIARRHEA; DRUG ACTIVITY; FEVER; HEADACHE; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE SYSTEM; IMMUNITY; IMMUNOTHERAPY; INFLUENZA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MYALGIA; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE;

EID: 2942519528     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.3.413     Document Type: Review

References (84)

1. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 34, 1436-1442 (1997).
2. Gwaltney JM. Viral respiratory infection therapy: historical perspectives and current trials. Am. J. Med. 11( Suppl. 6A), S33-S41 (2002).
3. Yamaya M, Sasaki H. Rhinovirus and asthma. Viral Immunol. 1, 99-109 (2003).
4. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2, 3068-3087 (2002).
5. McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br. Med. Bull. 6, 13-28 (2002).
6. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr. Respir. Rev. 5(Suppl. 1), S119-S126 (2004).
7. Cox NJ, Subbarao K. Influenza. Lancet 35, 1277-1282 (1999).
8. Lim WS, Macfarlane JT, Boswell TC et al. Study of community acquired pneumonia etiology (SCAPA) in adults admitted to hospital; implications for management guidelines. Thorax 5, 296-301 (2001).
9. Engelich G, White M, Hartshorn KL. Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. J. Leukoc. Biol. 6, 50-56 (2001).
10. Harrison TS. Cryptococcus neoformans and cryptococcosis. J. Infect. 4, 12-17 (2000).
11. Rodrigues ML, Alviano CS, Travassos LR. Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms. Microbes Infect. 1(4), 293-301 (1999).
12. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. 1, 637-646 (2003).
13. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J. Clin. Invest 10, 693-697 (2002).
14. Boyton RJ, Openshaw PJ. Pulmonary defences to acute respiratory infection. Br. Med. Bull. 6, 1-12 (2002).
15. Farnaud S, Evans RW. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol. Immunol. 4, 395-405 (2003).
16. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides, such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 62(Suppl. 2), ii17-ii21 (2003).
17. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defence. Ann. Rev. Immunol. 2, 547-578 (2003).
18. Gordon SB, Read RC. Macrophage defences against respiratory tract infections. Br. Med. Bull. 6, 45-61 (2002).
19. Wang SZ, Forsyth KD. The interaction of neutrophils with respiratory epithelial cells in viral infection. Respirology 5(1), 1-10 (2000).
20. Hayday A, Viney JL. The ins and outs of body surface immunology. Science 29, 97-100 (2000).
21. Lamm ME. Current concepts in mucosal immunity. IV. How epithelial transport of IgA antibodies relates to host defence. Am. J. Physiol. 27, G614-G617 (1998).
22. Julkunen I, Sareneva T, Pirhonen J, Ronni T, Melen K, Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 1, 171-180 (2001).
23. McIntosh K, Fishaut JM. Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus. Prog. Med. Virol. 2, 94-118 (1980).
24. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 8, 449-463 (1969).
25. Hussell T, Pennycook A, Openshaw PJM. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31, 2566-2573 (2001).
26. Peper RL, Van Campen H. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb. Pathog. 1, 175-183 (1995).
27. Kurokawa M, Imakita M, Kumeda CA, Shiraki K. Cascade of fever production in mice infected with influenza virus. J. Med. Virol. 5, 152-158 (1996).
28. Kozak W, Conn CA, Klir JJ, Wong GH, Kluger MJ. TNF soluble receptor and antiserum against TNF enhance lipopolysaccharide fever in mice. Am. J. Physiol. 26, R23-R29 (1995).
29. Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger MJ. Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am. J. Physiol. 27, R621-R630 (1997).
30. Cook DN. The role of MIP-1α in inflammation and hematopoiesis. J. Leukoc. Biol. 5, 61-66 (1996).
31. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin-8 gene region in UK families. Thorax 5, 1023-1027 (2000).
32. Becker S, Soukup JM. Airway epithelial cell-induced activation of monocytes and eosinophils in respiratory syncytial viral infection. Immunobiology 20, 88-106 (1999).
33. Panuska JR, Merolla R, Rebert NA et al. Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages - suppression of early cytokine production and implications for incomplete immunity. J. Clin. Invest. 9, 2445-2453 (1995).
34. Suliman HB, Ryan LK, Bishop L, Folz RJ. Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase. Am. J. Physiol. Lung Cell. Mol. Physiol. 28, L69-L78 (2001).
35. Akaike T. Role of free radicals in viral pathogenesis and mutation. Rev. Med. Virol. 1, 87-101 (2001).
36. Small BA, Dressel SA, Lawrence CW et al. CD8(+) T-cell-mediated injury in vivo progresses in the absence of effector T-cells. J. Exp. Med. 19, 1835-1846 (2001).
37. Wiley JA, Cerwenka A, Harkema JR, Dutton RW, Harmsen AG. Production of interferon-γ by influenza hemagglutinin-specific CD8 effector T-cells influences the development of pulmonary immunopathology. Am. J. Pathol. 15, 119-130 (2001).
38. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T-lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 8, 1026-1033 (1991).
39. Ostler T, Davidson W, Ehl S. Virus clearance and immunopathology by CD8(+) T-cells during infection with respiratory syncytial virus are mediated by IFN-γ. Eur. J. Immunol. 3, 2117-2123 (2002).
40. Alwan WH, Kozlowska WJ, Openshaw PJM. Distinct types of lung disease caused by functional subsets of antiviral T-cells. J. Exp. Med. 17, 81-89 (1994).
41. Boelen A, Kwakkel J, Barends M, de Rond L, Dormans J, Kimman T. Effect of lack of interleukin-4, interleukin-12, interleukin-18, or the interferon-γ receptor on virus replication, cytokine response and lung pathology during respiratory syncytial virus infection in mice. J. Med. Virol. 6, 552-560 (2002).
42. Renzi PM, Turgeon JP, Marcotte JE et al. Reduced interferon-γ production in infants with bronchiolitis and asthma. Am. J. Respir. Crit. Care Med. 15, 1417-1422 (1999).
43. Roman M, Calhoun WJ, Hinton KL et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am. J. Respir. Crit. Care Med. 15, 190-195 (1997).
44. Renzi PM, Turgeon JP, Yang JP et al. Cellular immunity is activated and a Th-2 response is associated with early wheezing in infants after bronchiolitis. J. Pediatr. 13, 584-593 (1997).
45. Berry AM, Alexander JE, Mitchell TJ, Andrew PW, Hausman D, Paton JC. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect. Immun. 6, 1969-1974 (1995).
46. Canvin JR, Marvin AP, Sivakumaran M et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a Type 2 pneumococcus. J. Infect. Dis. 17, 119-123 (1995).
47. Paton JC, Andrew PW, Boulnois GJ, Mitchell TJ. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Ann. Rev. Microbiol. 4, 89-115 (1993).
48. Blue CE, Paterson GK, Kerr AR, Berge M, Claverys JP, Mitchell TJ. ZmpB, a novel virulence factor of Streptococcus pneumoniae that induces tumor necrosis factor-α production in the respiratory tract. Infect. Immun. 7, 4925-4935 (2003).
49. Fenton MJ, Vermeulen MW. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect. Immun. 6, 683-690 (1996).
50. Kyd JM, Foxwell AR, Cripps AW. Mucosal immunity in the lung and upper airway. Vaccine 1, 2527-2533 (2001).
51. Poland GA, Rottinghaus ST, Jacobson RM. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 1, 2216-2220 (2001).
52. Nicholson KG, Wood JM, Zambon M. Influenza. Lancer 36, 1733-1745 (2003).
53. Hilleman MR. Serologic responses to split and whole swine influenza virus vaccines in light of the next influenza pandemic. J. Infect. Dis. 136(Suppl.), S683-S685 (1977).
54. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur. Respir. J. 1, 1282-1293 (2001).
55. Kendal AP. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. 1, 591-609 (1997).
56. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 33, 1405-1412 (1998).
57. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann. Rev. Immunol. 1, 617-648 (1997).
58. Ulmer JB, Donnelly JJ, Parker et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 25, 1745-1749 (1993).
59. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jon WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Med. 5(10), 1157-1163 (1999).
60. Hayden FG, Osterhaus AD, Treanor JJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N. Engl. J. Med. 33, 874-880 (1997).
61. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 35, 1845-1850 (2000).
62. Bachmann MF, Kopf M. Balancing protective immunity and immunopathology. Curr. Opin. Immunol. 1, 413-419 (2002).
63. Wilkinson KA, Martin TD, Reba SM et al. Latency-associated peptide of transforming growth factor-β enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice. Infect. Immun. 6, 6505-6508 (2000).
64. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor-α in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 6, 257-260 (1997).
65. Nauciel C, Espinasse-Maes F. Role of γ-interferon and tumor necrosis factor-α in resistance to Salmonella typhimurium infection. Infect. Immun. 6, 450-454 (1992).
66. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N. Engl. J. Med. 34, 1098-1104 (2001).
67. Hart PH, Ahern MJ, Smith MD, Finlay-Jones JJ. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Immunology 8, 536-542 (1995).
68. Hart PH, Jones CA, Finlay-Jones JJ. Monocytes cultured in cytokine-defined environments differ from freshly isolated monocytes in their responses to IL-4 and IL-10. J. Leukoc. Biol. 5, 909-918 (1995).
69. Morrison DF, Foss DL, Murtaugh MP. Interleukin-10 gene therapy-mediated amelioration of bacterial pneumonia. Infect. Immun. 6, 4752-4758 (2000).
70. Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J. Immunol. 15, 2858-2866 (1997).
71. Standiford TJ, Wilkowski JM, Sisson TH et al. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine Gram-negative pneumonia. Hum. Gene Ther. 1, 899-909 (1999).
72. van Der PT, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J. Infect. Dis. 17, 994-1000 (1996).
73. Kunkel SL, Lukacs NW, Strieter RM, Chensue SW. The role of chemokines in the immunopathology of pulmonary disease. Forum (Genova.) 9(4), 339-355 (1999).
74. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 12, S41-S50 (2004).
75. Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. A critical role for OX40 in T-cell-mediated immunopathology during lung viral infection. J. Exp. Med. 19, 1237-1242 (2003).
76. Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of Type 1 T-helper cells (Th1s) and Th2s. J. Exp. Med. 18, 129-134 (1998).
77. Loetscher P, Uguccioni M, Bordoli L et al. CCR5 is characteristic of Th1 lymphocytes (letter). Nature 39, 344-345 (1998).
78. Xu D, Chan WL, Leung BP et al. Selective expression of a stable cell surface molecule on Type 2 but not Type 1 helper T-cells. J. Exp. Med. 18, 787-794 (1998).
79. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 8, 973-983 (1996).
80. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T-cells. Cell 8, 587-596 (1997).
81. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T-helper 1 and 2 lymphocytes. J. Exp. Med. 18, 875-883 (1998).
82. Walzl G, Matthews S, Kendall S et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T-helper cell Type 2 (Th2)- but not Th1-driven immunopathology. J. Exp. Med. 19, 785-792 (2001).
83. Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T-cells. Immunity 1, 637-646 (2001).
84. Humphreys IR, Edwards L, Walzl G et al. OX40 ligation on activated T-cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J. Immunol. 17, 6125-6132 (2003).